CN113072497B - 蛋白酶抑制剂、其制备和用途 - Google Patents

蛋白酶抑制剂、其制备和用途 Download PDF

Info

Publication number
CN113072497B
CN113072497B CN202110336891.8A CN202110336891A CN113072497B CN 113072497 B CN113072497 B CN 113072497B CN 202110336891 A CN202110336891 A CN 202110336891A CN 113072497 B CN113072497 B CN 113072497B
Authority
CN
China
Prior art keywords
alkyl
compound
occurrence
pharmaceutically acceptable
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110336891.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113072497A (zh
Inventor
于洪涛
胡奇
黄晶
王廷亮
侯宁可
张莉婧
张文艺
谭巧珠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xihu Pharmaceutical Hangzhou Co ltd
Original Assignee
Xihu Pharmaceutical Hangzhou Co ltd
Westlake University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xihu Pharmaceutical Hangzhou Co ltd, Westlake University filed Critical Xihu Pharmaceutical Hangzhou Co ltd
Priority to CN202310629540.5A priority Critical patent/CN116751164B/zh
Publication of CN113072497A publication Critical patent/CN113072497A/zh
Application granted granted Critical
Publication of CN113072497B publication Critical patent/CN113072497B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202110336891.8A 2021-01-12 2021-03-29 蛋白酶抑制剂、其制备和用途 Active CN113072497B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310629540.5A CN116751164B (zh) 2021-01-12 2021-03-29 蛋白酶抑制剂、其制备和用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2021/071256 WO2022150962A1 (en) 2021-01-12 2021-01-12 Protease inhibitors, preparation, and uses thereof
CNPCT/CN2021/071256 2021-01-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310629540.5A Division CN116751164B (zh) 2021-01-12 2021-03-29 蛋白酶抑制剂、其制备和用途

Publications (2)

Publication Number Publication Date
CN113072497A CN113072497A (zh) 2021-07-06
CN113072497B true CN113072497B (zh) 2023-04-14

Family

ID=75277880

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110336891.8A Active CN113072497B (zh) 2021-01-12 2021-03-29 蛋白酶抑制剂、其制备和用途
CN202310629540.5A Active CN116751164B (zh) 2021-01-12 2021-03-29 蛋白酶抑制剂、其制备和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310629540.5A Active CN116751164B (zh) 2021-01-12 2021-03-29 蛋白酶抑制剂、其制备和用途

Country Status (5)

Country Link
US (1) US11958830B2 (cg-RX-API-DMAC7.html)
EP (1) EP4026830A1 (cg-RX-API-DMAC7.html)
JP (1) JP7611045B2 (cg-RX-API-DMAC7.html)
CN (2) CN113072497B (cg-RX-API-DMAC7.html)
WO (1) WO2022150962A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019216264B2 (en) 2018-01-31 2023-08-31 Heparegenix Gmbh Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2019243315A1 (en) 2018-06-21 2019-12-26 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
SG11202012732UA (en) 2018-07-16 2021-02-25 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP7629442B2 (ja) 2019-07-29 2025-02-13 ヘパリジェニックス ゲーエムベーハー 肝臓再生を促進または肝細胞死を縮減もしくは防止するためのヘテロアリール置換ピラゾロ-ピリジンタンパク質キナーゼ阻害剤
CA3164361A1 (en) 2020-01-15 2021-07-22 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
JP2024178473A (ja) * 2021-09-03 2024-12-25 塩野義製薬株式会社 ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
WO2023036140A1 (zh) 2021-09-07 2023-03-16 上海齐鲁制药研究中心有限公司 3CLpro蛋白酶抑制剂
CR20250040A (es) 2022-08-05 2025-03-18 Gilead Sciences Inc Inhibidores de la proteasa principal de sars-cov2
US20240158368A1 (en) 2022-10-14 2024-05-16 Abbvie Inc. Pyrrolidine Main Protease Inhibitors as Antiviral Agents
WO2024124287A1 (en) * 2022-12-12 2024-06-20 The Walter And Eliza Hall Institute Of Medical Research Compounds for treating viral infection
CN120787158A (zh) * 2023-03-03 2025-10-14 齐鲁动物保健品有限公司 3CLpro蛋白酶抑制剂在制备治疗猫冠状病毒疾病药物中的用途
JP2026515483A (ja) * 2023-04-11 2026-05-18 ウエストレイク ファーマシューティカルズ (ハンチョウ) カンパニー、リミテッド プロテアーゼ阻害剤及びその使用
WO2024243841A1 (zh) 2023-05-31 2024-12-05 西湖制药(杭州)有限公司 一种病毒蛋白酶抑制剂的结晶及用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK175069B1 (da) * 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US6335350B1 (en) 1998-12-09 2002-01-01 American Home Products Corporation Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
CN1333750A (zh) * 1998-12-09 2002-01-30 美国家庭用品有限公司 含乙酰胺和取代的乙酰胺的疱疹病毒硫脲抑制剂
EP1137632B1 (en) * 1998-12-09 2004-07-28 Wyeth Thiourea inhibitors of herpes viruses
TW200306159A (en) 2002-03-19 2003-11-16 Du Pont Bicyclic fused pyridinyl amides and advantageous compositions thereof for use as fungicides
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7067529B2 (en) 2003-05-19 2006-06-27 Hoffmann-La Roche Inc. Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors
EP1652525A4 (en) * 2003-07-15 2008-10-01 Arigen Inc ANTI-VIRUS CORONA DRUG
US7732446B1 (en) * 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2008532933A (ja) * 2005-02-11 2008-08-21 コーリー ファーマシューティカル グループ,インコーポレイテッド 置換イミダゾキノリン類および置換イミダゾナフチリジン類
EP2124568A1 (en) * 2007-01-17 2009-12-02 Merck & Co., Inc. Decahydroquinoline analogs as cb2 receptor modulators
CN101519372B (zh) * 2009-04-01 2011-07-20 深圳市盛捷生物技术有限公司 用作GSK3抑制剂的苯并[e]异吲哚-1,3-二酮化合物及其制备
WO2011151423A1 (en) 2010-06-04 2011-12-08 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
WO2012090177A2 (en) * 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CN104334532B (zh) * 2012-01-30 2018-08-14 霍夫曼-拉罗奇有限公司 异喹啉和二氮杂萘衍生物
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
IN2014MN01982A (cg-RX-API-DMAC7.html) * 2012-04-25 2015-07-10 Raqualia Pharma Inc
WO2014025651A1 (en) 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
PL2953941T3 (pl) 2013-02-11 2017-11-30 Constellation Pharmaceuticals, Inc. Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
KR101715090B1 (ko) * 2013-08-28 2017-03-13 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
KR20150027922A (ko) 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
WO2016036638A1 (en) * 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
EP4006012A1 (en) * 2015-10-15 2022-06-01 Cornell University Proteasome inhibitors and uses thereof
EP3478662B1 (en) * 2016-06-30 2020-09-16 ViiV Healthcare UK (No.5) Limited Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
CN107674029A (zh) * 2016-08-02 2018-02-09 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
US11247970B2 (en) 2017-03-22 2022-02-15 Dana-Farber Cancer Institute, Inc. Selective inhibition of gluconeogenic activity
TWI821343B (zh) 2018-07-27 2023-11-11 美商共結晶製藥公司 流感病毒複製之抑制劑
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
EP3982954A4 (en) * 2019-06-14 2024-01-03 The Trustees of Columbia University in the City of New York NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA

Also Published As

Publication number Publication date
US11958830B2 (en) 2024-04-16
US20220227731A1 (en) 2022-07-21
JP2022108241A (ja) 2022-07-25
JP7611045B2 (ja) 2025-01-09
CN116751164B (zh) 2026-03-13
WO2022150962A1 (en) 2022-07-21
EP4026830A1 (en) 2022-07-13
CN116751164A (zh) 2023-09-15
CN113072497A (zh) 2021-07-06

Similar Documents

Publication Publication Date Title
CN116751164B (zh) 蛋白酶抑制剂、其制备和用途
CN114507221B (zh) 一种三嗪类化合物及其在制备抗病毒药物上的用途
WO2023173708A1 (zh) 三嗪类化合物或其可药用盐、异构体、药物组合物和用途
MD3953330T2 (ro) Compuși care conțin nitril utili în calitate de agenți antivirali pentru tratamentul infecției cu coronavirus
ES2321249T3 (es) Inhibidores de proteasa multicalitica a base de alfa-acetoamidas.
TW202321251A (zh) 新穎螺環吡咯啶衍生的抗病毒劑
CN103717067A (zh) 制备大环内酰胺的方法与中间体
KR20140097197A (ko) 피리미딘-4-온 유도체 및 바이러스성 질환을 치료, 개선 또는 예방하는데 있어서의 이들의 용도
KR20140100476A (ko) 헤테로아릴 하이드록삼산 유도체 및 바이러스성 질환을 치료, 개선 또는 예방하는데 있어서의 이들의 용도
CN115160301B (zh) 一种山荷叶素衍生物、其制备方法及用途
HK40050067B (en) Protease inhibitors, preparation, and uses thereof
HK40050067A (en) Protease inhibitors, preparation, and uses thereof
WO2016107227A1 (zh) 吡咯酰胺类化合物及其制备方法与用途
CN118176202B (zh) 一种含氰基取代的多肽类化合物的晶型及其制备方法
CN115385984B (zh) 一种拟肽类衍生物、制备方法和应用
HK40077416A (en) Protease inhibitors, preparation, and uses thereof
CN114621204B (zh) 一种含有嘧啶二酮酰基多取代哌嗪类衍生物及其制备方法与应用
WO2022156693A1 (zh) 含有n-(取代磺酰基)乙酰胺结构的病毒蛋白酶抑制剂,及其在抗病毒药物中的应用
CN107619392A (zh) 1h‑吲唑‑4‑醚类化合物及其作为ido抑制剂的用途
WO2016107541A1 (zh) 吡咯酰胺类化合物及其制备方法与用途
CN105732458B (zh) 吡咯酰胺类化合物及其制备方法与用途
WO2024212101A1 (en) Protease inhibitors and uses thereof
WO2026021477A1 (zh) 氮杂并环类化合物及其药物组合物和应用
RU2827891C1 (ru) Фармацевтическая композиция, включающая производное 1,3,5-триазин-2,4-диамина, для ингибирования репликации бета-коронавирусов, включая sars-cov-2, и способ ее применения
WO2024146631A1 (zh) 一种parp7抑制剂的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050067

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220510

Address after: 310024 room 666, building 1, No. 1, Yunmeng Road, Zhuantang street, Xihu District, Hangzhou, Zhejiang

Applicant after: Xihu Pharmaceutical (Hangzhou) Co.,Ltd.

Address before: No.18 Shilongshan street, Yunqi Town, Xihu District, Hangzhou City, Zhejiang Province, 310024

Applicant before: WESTLAKE University

GR01 Patent grant
GR01 Patent grant